Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_assertion description "[For a long period of time, the standard therapy for MDS was hematopoietic stem cell transplantation, however DNA methyltransferase inhibitors (DNMT inhibitors) including decitabine (DAC) and azacitidine (AZA), and lenalidomide, a derivative of thalidomide have been highlighted as new chemotherapeutic agents for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_assertion evidence source_evidence_literature NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_assertion SIO_000772 22571700 NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_assertion wasDerivedFrom befree-20140225 NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_assertion wasGeneratedBy ECO_0000203 NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.
- befree-20140225 importedOn "2014-02-25" NP909203.RAHFIvw71woIxumormK4cqLEEXtZDeU8ckNXD85IphXVQ130_provenance.